Shanghai Vitalgen BioPharma Co., Ltd, a specialist in cell and gene therapy based in China, has entered into a licensing agreement with Suzhou Novoprotein Scientific Co., Ltd, a provider of protein technology and application solutions. Under the terms of the agreement, Novoprotein will secure manufacturing and marketing licenses for AaCas12bMax GMP grade and RUO grade proteins, marking a significant step in the commercialization of gene and cell therapy tools.
The partnership is designed to jointly advance the commercial application of AaCas12bMax within the gene and cell therapy drug sector, offering comprehensive support across the drug development spectrum, from discovery and preclinical research to IND application, clinical trials, new drug application (BLA), and ultimately, market launch.
Capitalizing on the naturally low off-target effects of the Cas12b family, Vitalgen’s AaCas12bMax, a clinical-grade ‘zero off-target’ gene editor, has been further refined through the MIDAS protein engineering system. This optimization has resulted in a gene editing tool with ‘zero off-target’ activity and high editing efficiency in mammalian cells. AaCas12bMax exhibits a significantly lower potential for off-target editing sites and probability compared to Cas9 and Cas12a, enhancing the safety profile of gene editing. Moreover, the cell viability and proliferation rates post-editing with AaCas12bMax are considerably higher than those achieved with Cas9, indicating its promising clinical application potential. The system is already being utilized in multiple pipelines by various companies.- Flcube.com
